JP2011520885A - 抗ｃｘｃｒ４抗体 - Google Patents

抗ｃｘｃｒ４抗体 Download PDF

Info

Publication number
JP2011520885A
JP2011520885A JP2011509562A JP2011509562A JP2011520885A JP 2011520885 A JP2011520885 A JP 2011520885A JP 2011509562 A JP2011509562 A JP 2011509562A JP 2011509562 A JP2011509562 A JP 2011509562A JP 2011520885 A JP2011520885 A JP 2011520885A
Authority
JP
Japan
Prior art keywords
seq
human
antibody
cancer
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011509562A
Other languages
English (en)
Japanese (ja)
Inventor
シンディ・タケウチ・ディッカーソン
デイビッド・マシュー・マーキス
ビクター・オブング
シェン−ビン・ペン
ピーター・エドワード・ベイランコート
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2011520885A publication Critical patent/JP2011520885A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011509562A 2008-05-14 2009-05-07 抗ｃｘｃｒ４抗体 Withdrawn JP2011520885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5319208P 2008-05-14 2008-05-14
US61/053,192 2008-05-14
PCT/US2009/043063 WO2009140124A1 (fr) 2008-05-14 2009-05-07 Anticorps anti-cxcr4

Publications (1)

Publication Number Publication Date
JP2011520885A true JP2011520885A (ja) 2011-07-21

Family

ID=40852496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509562A Withdrawn JP2011520885A (ja) 2008-05-14 2009-05-07 抗ｃｘｃｒ４抗体

Country Status (11)

Country Link
EP (1) EP2297206A1 (fr)
JP (1) JP2011520885A (fr)
KR (1) KR20100133012A (fr)
CN (1) CN102027015A (fr)
AU (1) AU2009246683A1 (fr)
CA (1) CA2724409A1 (fr)
EA (1) EA201071300A1 (fr)
IL (1) IL208869A0 (fr)
MX (1) MX2010012435A (fr)
WO (1) WO2009140124A1 (fr)
ZA (1) ZA201007955B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525129A (ja) * 2009-04-29 2012-10-22 ピエール、ファーブル、メディカマン Ｈｉｖ治療のための抗ｃｘｃｒ４抗体

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (fr) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer
EP2396023A2 (fr) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Peptides courts dérivés de bêta-défensine
WO2012055980A1 (fr) * 2010-10-27 2012-05-03 Pierre Fabre Medicament Anticorps utilisés pour traiter le vih
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (fr) 2011-06-24 2012-12-27 Gillies Stephen D Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
BR112014011144A2 (pt) * 2011-11-09 2017-05-16 Bristol Myers Squibb Co tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
EP3765519B1 (fr) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anticorps anti-cxcr4 combiné à des cellules tueuses naturelles activées et développées pour une immunothérapie anticancéreuse
KR20200136454A (ko) 2018-03-27 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
WO2020172658A1 (fr) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Procédés d'isolement d'une protéine
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
WO2023173011A1 (fr) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801265C1 (de) * 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibierung von CD95-unabhängiger Apoptose bei AIDS
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
AU2007320024B2 (en) * 2006-10-02 2012-11-08 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525129A (ja) * 2009-04-29 2012-10-22 ピエール、ファーブル、メディカマン Ｈｉｖ治療のための抗ｃｘｃｒ４抗体

Also Published As

Publication number Publication date
MX2010012435A (es) 2011-05-03
WO2009140124A1 (fr) 2009-11-19
KR20100133012A (ko) 2010-12-20
CA2724409A1 (fr) 2009-11-19
IL208869A0 (en) 2011-01-31
ZA201007955B (en) 2012-04-25
EA201071300A1 (ru) 2011-06-30
EP2297206A1 (fr) 2011-03-23
CN102027015A (zh) 2011-04-20
AU2009246683A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
JP2011520885A (ja) 抗ｃｘｃｒ４抗体
JP7165217B2 (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
US10214586B2 (en) PD-L1 antibodies
JP7257364B2 (ja) 抗ｃｄ１３７抗体
JP5899310B2 (ja) ｃ−ＫＩＴ抗体およびその使用
US20200140562A1 (en) Anti-ox40 antibody and use thereof
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP6105146B2 (ja) Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体
US11440959B2 (en) CD226 agonist antibodies
US20230279134A1 (en) Anti-cd137 antibodies
TW201839009A (zh) 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
EP3145544B1 (fr) Anticorps anti-ang2
US8003102B2 (en) Anti-CXCR4 antibodies
WO2017122666A1 (fr) Anticorps anti-myl9
US20200157234A1 (en) Anti-cd137 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121108